AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12689735 — intervention group
Group type: EXPERIMENTAL
Intervention: Joint distribution of nonterminal event time estimation
Number of subjects: 0
Study 12689735 — intervention group
Group type: EXPERIMENTAL
Intervention: Tests for independence and goodness-of-fit of the model
Number of subjects: 0
Study 12689735 — intervention group
Group type: EXPERIMENTAL
Intervention: Marginal distribution of the nonterminal event
Number of subjects: 0
Study 10921699 — intervention group
Group type: EXPERIMENTAL
Intervention: GIK (500 mL D5W + 80 U regular insulin + 40 mEq KCl at 30 mL/hour)
Number of subjects: 40
Study 10921699 — intervention group
Group type: COMPARATOR
Intervention: No-GIK (D5W at 30 mL/hour)
Number of subjects: 40
Study 8923553 — intervention group
Group type: EXPERIMENTAL
Intervention: Large display viewed at 1 m
Number of subjects: 0
Study 8923553 — intervention group
Group type: EXPERIMENTAL
Intervention: Small display viewed at 33.3 cm (equal retinal size to large display at 1 m)
Number of subjects: 0
Study 8923553 — intervention group
Group type: COMPARATOR
Intervention: Small display viewed at 1 m
Number of subjects: 0
Study 1600045 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg ranitidine
Number of subjects: 20
Study 1600045 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 3518290 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambroxol 1,000 mg in 500 ml 5% glucose infusion i.v. daily from day 1 to day 5 and 2 ml placebo‐injection i.m. on day 1 and day 2
Number of subjects: 34
Study 3518290 — intervention group
Group type: COMPARATOR
Intervention: Betamethasone 8 mg i.m. on day 1 and day 2 and 500 ml 5% glucose infusion with a placebo daily from day 1 to day 5
Number of subjects: 34
Study 28043722 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic‐assisted total laparoscopic hysterectomy
Number of subjects: 20
Study 28043722 — intervention group
Group type: COMPARATOR
Intervention: Abdominal hysterectomy
Number of subjects: 20
Study 27792174 — intervention group
Group type: EXPERIMENTAL
Intervention: Vegetarian diet (V)
Number of subjects: 74
Study 27792174 — intervention group
Group type: COMPARATOR
Intervention: Conventional diet (C)
Number of subjects: 74
Study 23696633 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab (IFX) plus naproxen (NPX) 1000 mg daily
Number of subjects: 156
Study 23696633 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PBO) plus naproxen (NPX) 1000 mg daily
Number of subjects: 156
Study 22079769 — intervention group
Group type: EXPERIMENTAL
Intervention: Glenoid component with inferior tilt (10°)
Number of subjects: 52
Study 22079769 — intervention group
Group type: COMPARATOR
Intervention: Control group with no inferior tilt
Number of subjects: 52
Study 21714711 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin titrated from 10-80 mg/day aiming at LDL-C target of <100 mg/dl (group A)
Number of subjects: 1123
Study 21714711 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin titrated from 10-80 mg/day aiming at LDL-C target of <130 mg/dl (group B)
Number of subjects: 1123
Study 19352377 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplementation (10 microg/day)
Number of subjects: 173
Study 19352377 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplementation (20 microg/day)
Number of subjects: 173
Study 19352377 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 173
Study 16749569 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A: Anesthesia induced with fentanyl 2 microg/kg and propofol 2-3 mg/kg, maintained with isoflurane 0.8-1.2% and fentanyl infusion 1-2 mcg/kg/h
Number of subjects: 20
Study 16749569 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B: Anesthesia induced with sufentanyl 0.2 mcg/kg and propofol 2-3 mg/kg, maintained with propofol infusion 6-12 mg/kg/h and sufentanyl infusion 0.2-0.4 mcg/kg/h
Number of subjects: 20
Study 15277618 — intervention group
Group type: EXPERIMENTAL
Intervention: frovatriptan 2.5 mg QD
Number of subjects: 546
Study 15277618 — intervention group
Group type: EXPERIMENTAL
Intervention: frovatriptan 2.5 mg BID
Number of subjects: 546
Study 15277618 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 546
Study 10945314 — intervention group
Group type: EXPERIMENTAL
Intervention: Methoxsalen 10 mg plus nicotine 4 mg
Number of subjects: 28
Study 10945314 — intervention group
Group type: EXPERIMENTAL
Intervention: Methoxsalen 30 mg plus nicotine 4 mg
Number of subjects: 28
Study 10945314 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus nicotine 4 mg
Number of subjects: 28
Study 10945314 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus placebo
Number of subjects: 28
Study 9455085 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural anesthesia (EA)
Number of subjects: 77
Study 9455085 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia (GA)
Number of subjects: 77
Study 8404790 — intervention group
Group type: EXPERIMENTAL
Intervention: Wheat Bran (WB)
Number of subjects: 17
Study 8404790 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugarbeet Fiber (SBF)
Number of subjects: 17
Study 8404790 — intervention group
Group type: COMPARATOR
Intervention: Self-Selected Diet (SS)
Number of subjects: 17
Study 3811806 — intervention group
Group type: EXPERIMENTAL
Intervention: Halothane
Number of subjects: 28
Study 3811806 — intervention group
Group type: COMPARATOR
Intervention: Enflurane
Number of subjects: 28
Study 29443653 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy (CT)
Number of subjects: 162
Study 29443653 — intervention group
Group type: COMPARATOR
Intervention: No Chemotherapy (no CT)
Number of subjects: 162
Study 27099924 — intervention group
Group type: EXPERIMENTAL
Intervention: High in industrial TFA (iTFA; 3.7% energy)
Number of subjects: 9
Study 27099924 — intervention group
Group type: EXPERIMENTAL
Intervention: High in TFA from ruminants (rTFA; 3.7% energy)
Number of subjects: 9
Study 27099924 — intervention group
Group type: COMPARATOR
Intervention: Low in TFA (control; 0.8% energy)
Number of subjects: 9
Study 24887252 — intervention group
Group type: EXPERIMENTAL
Intervention: Caudal bupivacaine 0.25% at 1 ml/kg and neostigmine 1.5 ug/kg
Number of subjects: 66
Study 24887252 — intervention group
Group type: COMPARATOR
Intervention: Caudal bupivacaine 0.25% at 1 ml/kg
Number of subjects: 66
Study 21655934 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-based patient education
Number of subjects: 311
Study 21655934 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional education with standard leaflets
Number of subjects: 311
Study 21655934 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard treatment
Number of subjects: 311
Study 20378840 — intervention group
Group type: EXPERIMENTAL
Intervention: 28 g/day textured soy flour (containing 14 g of soy protein) for 8 weeks
Number of subjects: 40
Study 20378840 — intervention group
Group type: COMPARATOR
Intervention: Usual diet without any soy
Number of subjects: 40
Study 17826960 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocaine/adrenaline application to the nasal floor
Number of subjects: 30
Study 17826960 — intervention group
Group type: COMPARATOR
Intervention: Control group (no cocaine/adrenaline application)
Number of subjects: 30
Study 15703206 — intervention group
Group type: EXPERIMENTAL
Intervention: Lanthanum carbonate (375 mg/day, titrated up to 2250 mg)
Number of subjects: 59
Study 15703206 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study 15703206 — intervention group
Group type: EXPERIMENTAL
Intervention: Lanthanum carbonate
Number of subjects: 59
Study 12437457 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% imiquimod cream
Number of subjects: 36
Study 12437457 — intervention group
Group type: COMPARATOR
Intervention: Vehicle cream
Number of subjects: 36
Study 10352370 — intervention group
Group type: EXPERIMENTAL
Intervention: Whirl bath with valerian (n = 12)
Number of subjects: 30
Study 10352370 — intervention group
Group type: EXPERIMENTAL
Intervention: Whirl bath with pine oil (n = 7)
Number of subjects: 30
Study 10352370 — intervention group
Group type: EXPERIMENTAL
Intervention: Whirl bath with plain water (n = 11)
Number of subjects: 30
Study 8942593 — intervention group
Group type: EXPERIMENTAL
Intervention: Wound infiltration with tenoxicam 7.5 mg in 40 mL of 0.9% saline (WI group)
Number of subjects: 50
Study 8942593 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular tenoxicam 7.5 mg (IM group)
Number of subjects: 50
Study 1822480 — intervention group
Group type: EXPERIMENTAL
Intervention: Nursing intervention program including four 1 1/2 hour classes held at weekly intervals, selected maternal‐fetal interactive activities, recording of fetal movements, and maintaining of maternal diaries
Number of subjects: 20
Study 1822480 — intervention group
Group type: EXPERIMENTAL
Intervention: Nursing intervention program
Number of subjects: 20
Study 1822480 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 20
Study 7035049 — intervention group
Group type: EXPERIMENTAL
Intervention: Penicillin V
Number of subjects: 198
Study 7035049 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzathine/procaine penicillin G
Number of subjects: 198
Study 7035049 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefadroxil monohydrate
Number of subjects: 198
Study 7035049 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin estolate
Number of subjects: 198
Study 30741494 — intervention group
Group type: EXPERIMENTAL
Intervention: sacubitril/valsartan 200 mg bid
Number of subjects: 8399
Study 30741494 — intervention group
Group type: COMPARATOR
Intervention: enalapril 10 mg bid
Number of subjects: 8399
Study 28851237 — intervention group
Group type: EXPERIMENTAL
Intervention: Active and Healthy Families (AHF) intervention
Number of subjects: 23
Study 28851237 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 23
Study 26025796 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g intravenous propacetamol
Number of subjects: 111
Study 26025796 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 g intravenous propacetamol
Number of subjects: 111
Study 24407163 — intervention group
Group type: EXPERIMENTAL
Intervention: Spanish-language Google AdWords campaign
Number of subjects: 2575
Study 24407163 — intervention group
Group type: EXPERIMENTAL
Intervention: English-language Google AdWords campaign
Number of subjects: 2575
Study 24407163 — intervention group
Group type: EXPERIMENTAL
Intervention: Broad keywords (e.g., pregnancy)
Number of subjects: 2575
Study 24407163 — intervention group
Group type: EXPERIMENTAL
Intervention: Spanish-speaking participants
Number of subjects: 2575
Study 22945206 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacotherapy
Number of subjects: 60
Study 22945206 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychotherapy
Number of subjects: 60
Study 22945206 — intervention group
Group type: EXPERIMENTAL
Intervention: Both pharmacotherapy and psychotherapy
Number of subjects: 60
Study 19255819 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity interventions
Number of subjects: 25
Study 16918891 — intervention group
Group type: EXPERIMENTAL
Intervention: Tegaserod 6 mg twice daily
Number of subjects: 41
Study 16918891 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study 15298648 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine plus fluvoxamine
Number of subjects: 20
Study 15298648 — intervention group
Group type: COMPARATOR
Intervention: Olanzapine alone
Number of subjects: 20
Study 11783602 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive insulin therapy (3 daily injections of regular insulin and 1 or 2 daily injections of intermediate acting insulin associated with metformin 500 mg twice daily in 64% of patients) in Group B (a) to achieve HbA1c < 7.5%.
Number of subjects: 88
Study 11783602 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (850 mg thrice daily) in Group B (b) to achieve HbA1c < 7.5%.
Number of subjects: 88
Study 11783602 — intervention group
Group type: COMPARATOR
Intervention: Conventional metabolic therapy (sulphonylureas and/or biguanides) in Group A.
Number of subjects: 88
Study 11783602 — intervention group
Group type: COMPARATOR
Intervention: Control of blood pressure using ACE inhibitors, beta blockers, calcium antagonists, and/or thiazides.
Number of subjects: 88
Study 11783602 — intervention group
Group type: EXPERIMENTAL
Intervention: Not applicable (comparison of GFR decay between groups).
Number of subjects: 88
Study 9408691 — intervention group
Group type: EXPERIMENTAL
Intervention: Urodilatin at a dose of 20 ng/kg/min for 7 days
Number of subjects: 70
Study 9408691 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusion for 7 days
Number of subjects: 70
Study 8381081 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.6 mmol.kg body mass‐1 NaHCO3 (test, T)
Number of subjects: 6
Study 8381081 — intervention group
Group type: COMPARATOR
Intervention: 3.0 mmol.kg body mass‐1 CaCO3 (placebo, P)
Number of subjects: 6
Study 3595071 — intervention group
Group type: EXPERIMENTAL
Intervention: Anirolac, 100 mg
Number of subjects: 120
Study 3595071 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen, 550 mg
Number of subjects: 120
Study 3595071 — intervention group
Group type: EXPERIMENTAL
Intervention: Anirolac, 50 mg
Number of subjects: 120
Study 3595071 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 3595071 — intervention group
Group type: EXPERIMENTAL
Intervention: All active agents (Anirolac 50 mg, Anirolac 100 mg, Naproxen 550 mg)
Number of subjects: 120
Study 31629852 — intervention group
Group type: EXPERIMENTAL
Intervention: CoQ10 (400 mg per day)
Number of subjects: 123
Study 31629852 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 123
Study 31629852 — intervention group
Group type: EXPERIMENTAL
Intervention: CoQ10
Number of subjects: 123
Study 29635501 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight-for-height or -length z score (WHZ) ≥ -2 at month 1
Number of subjects: 1778
Study 29635501 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight-for-height or -length z score (WHZ) ≥ -2 at month 3
Number of subjects: 1778
Study 29635501 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight-for-height or -length z score (WHZ) ≥ -2 at month 6
Number of subjects: 1778
Study 29635501 — intervention group
Group type: COMPARATOR
Intervention: Weight-for-height or -length z score (WHZ) < -3
Number of subjects: 1778
Study 28067532 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental stress-induced left ventricular ejection fraction change
Number of subjects: 310
Study 28067532 — intervention group
Group type: COMPARATOR
Intervention: Exercise stress-induced myocardial ischemia (ESIMI)
Number of subjects: 310
Study 26041872 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency (RF) ablation catheter with integrated force sensor (TactiCath™) following EFFICAS I-based contact force (CF) guidelines (target 20 g, range 10-30 g, minimum 400 g s force-time integral).
Number of subjects: 24
Study 26041872 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency (RF) ablation catheter with integrated force sensor (TactiCath™) following EFFICAS I-based contact force (CF) guidelines.
Number of subjects: 24
Study 26041872 — intervention group
Group type: COMPARATOR
Intervention: Not applicable (control group from EFFICAS I).
Number of subjects: 24
Study 26041872 — intervention group
Group type: EXPERIMENTAL
Intervention: Not applicable (comparison of number of lesions).
Number of subjects: 24
Study 23890931 — intervention group
Group type: EXPERIMENTAL
Intervention: Diuretic (hydrochlorothiazide 25 mg)
Number of subjects: 140
Study 23890931 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin-converting enzyme inhibitor, angiotensin receptor blocker, or calcium channel blocker
Number of subjects: 140
Study 23890931 — intervention group
Group type: EXPERIMENTAL
Intervention: Uncontrolled RH treatment
Number of subjects: 140
Study 21940597 — intervention group
Group type: EXPERIMENTAL
Intervention: HAMSB40 (40 g cooked high‐amylose maize starch with 31.8 mmol esterified butyrate)
Number of subjects: 16
Study 21940597 — intervention group
Group type: EXPERIMENTAL
Intervention: HAMSB20 (20 g cooked high‐amylose maize starch with 31.8 mmol esterified butyrate)
Number of subjects: 16
Study 21940597 — intervention group
Group type: COMPARATOR
Intervention: HAMS (control group with high‐amylose maize starch)
Number of subjects: 16
Study 18310366 — intervention group
Group type: EXPERIMENTAL
Intervention: Exteriorized uterine repair
Number of subjects: 637
Study 18310366 — intervention group
Group type: COMPARATOR
Intervention: In situ uterine repair
Number of subjects: 637
Study 15220698 — intervention group
Group type: EXPERIMENTAL
Intervention: saquinavir 1000 mg/ritonavir 100 mg every 12 hours
Number of subjects: 11
Study 15220698 — intervention group
Group type: EXPERIMENTAL
Intervention: amprenavir 600 mg/ritonavir 100 mg every 12 hours
Number of subjects: 11
Study 11316688 — intervention group
Group type: EXPERIMENTAL
Intervention: Two antibiotics based on antibiotic susceptibility testing
Number of subjects: 150
Study 11316688 — intervention group
Group type: COMPARATOR
Intervention: Amoxycillin and clarithromycin for eight days, with either ranitidine or omeprazole
Number of subjects: 150
Study 9934029 — intervention group
Group type: EXPERIMENTAL
Intervention: Dressing A
Number of subjects: 0
Study 9934029 — intervention group
Group type: COMPARATOR
Intervention: Dressing B
Number of subjects: 0
Study 7591850 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenol alone
Number of subjects: 82
Study 7591850 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined exposure to phenol, benzene, toluene, methyl ethyl ketone
Number of subjects: 82
Study 7591850 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 82
Study 2500562 — intervention group
Group type: EXPERIMENTAL
Intervention: Total parenteral nutrition (TPN)
Number of subjects: 18
Study 2500562 — intervention group
Group type: COMPARATOR
Intervention: 5% dextrose
Number of subjects: 18
Study 16326376 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivalirudin
Number of subjects: 294
Study 16326376 — intervention group
Group type: COMPARATOR
Intervention: Eptifibatide
Number of subjects: 294
Study 31769845 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteric-coated Mycophenolate Sodium (EC-MPS) plus low-dose prednisolone (0.25 mg/kg/day)
Number of subjects: 20
Study 31769845 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose prednisolone (1 mg/kg/day)
Number of subjects: 20
Study 30878207 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-threshold group (n = 44)
Number of subjects: 126
Study 30878207 — intervention group
Group type: COMPARATOR
Intervention: High-threshold group (n = 44)
Number of subjects: 126
Study 28531828 — intervention group
Group type: EXPERIMENTAL
Intervention: CT-based evaluation for DNT
Number of subjects: 0
Study 28531828 — intervention group
Group type: COMPARATOR
Intervention: MRI-based evaluation for DNT
Number of subjects: 0
Study 25451384 — intervention group
Group type: EXPERIMENTAL
Intervention: Applied tension
Number of subjects: 98
Study 25451384 — intervention group
Group type: COMPARATOR
Intervention: No applied tension (Control)
Number of subjects: 98
Study 23211356 — intervention group
Group type: EXPERIMENTAL
Intervention: Continued dual antiplatelet therapy (DAPT)
Number of subjects: 2157
Study 23211356 — intervention group
Group type: COMPARATOR
Intervention: No continued dual antiplatelet therapy (DAPT)
Number of subjects: 2157
Study 21511223 — intervention group
Group type: EXPERIMENTAL
Intervention: Zotarolimus-eluting stent
Number of subjects: 2033
Study 21511223 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus-eluting stent
Number of subjects: 2033
Study 21511223 — intervention group
Group type: EXPERIMENTAL
Intervention: SYNTAX score (SXscore)
Number of subjects: 2033
Study 21511223 — intervention group
Group type: EXPERIMENTAL
Intervention: SYNTAX score (SXscore) tertiles
Number of subjects: 2033
Study 19403844 — intervention group
Group type: EXPERIMENTAL
Intervention: Stage II or III tumor
Number of subjects: 3088
Study 19403844 — intervention group
Group type: EXPERIMENTAL
Intervention: Poorly differentiated tumors
Number of subjects: 3088
Study 19403844 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive estrogen receptor status
Number of subjects: 3088
Study 17005078 — intervention group
Group type: EXPERIMENTAL
Intervention: Plavix and Erigeron Injection (EI)
Number of subjects: 72
Study 17005078 — intervention group
Group type: COMPARATOR
Intervention: Plavix alone (Control)
Number of subjects: 72
Study 15612492 — intervention group
Group type: EXPERIMENTAL
Intervention: Yogurt (Y)
Number of subjects: 24
Study 11085202 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicorandil
Number of subjects: 0
Study 9303286 — intervention group
Group type: EXPERIMENTAL
Intervention: Subpubic penile block
Number of subjects: 45
Study 9303286 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous ring block
Number of subjects: 45
Study 8367976 — intervention group
Group type: EXPERIMENTAL
Intervention: sustained‐release bezafibrate 400 mg daily (n = 21)
Number of subjects: 40
Study 8367976 — intervention group
Group type: COMPARATOR
Intervention: placebo (n = 19)
Number of subjects: 40
Study 3788835 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral-calcium supplementation (1500 mg Ca++/day for 6 wk)
Number of subjects: 58
Study 3788835 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study 30103241 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Number of subjects: 603
Study 30103241 — intervention group
Group type: COMPARATOR
Intervention: Prasugrel
Number of subjects: 603
Study 30103241 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP2C19*2 allele carriers in PGDE group
Number of subjects: 603
Study 26860642 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-eluting balloon
Number of subjects: 237
Study 26860642 — intervention group
Group type: COMPARATOR
Intervention: Standard balloon angioplasty
Number of subjects: 237
Study 26860642 — intervention group
Group type: EXPERIMENTAL
Intervention: Toe pressure measurements
Number of subjects: 237
Study 26860642 — intervention group
Group type: EXPERIMENTAL
Intervention: ABI, ankle pressure, toe pressure
Number of subjects: 237
Study 23945842 — intervention group
Group type: EXPERIMENTAL
Intervention: LESS cholecystectomy
Number of subjects: 57
Study 23945842 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic cholecystectomy (LC)
Number of subjects: 57
Study 22422777 — intervention group
Group type: COMPARATOR
Intervention: GnRH-antagonist (ganirelix or cetrorelix 0.25 mg starting on Day 6 of stimulation)
Number of subjects: 190